Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Innofiller is an injectable aesthetic product that has been marketed and distributed (notably by the now-closed Vivid-Scientific) as a Botulinum Toxin Type A neuromodulator. Despite a brand name that suggests a dermal filler and some distributor descriptions citing soft-tissue augmentation or volume loss, it is primarily categorized as a neurotoxin. It is used to treat aesthetic indications such as facial wrinkles and fine lines by inducing temporary muscle relaxation. The mechanism of action involves the proteolytic cleavage of SNAP-25, a protein essential for the release of acetylcholine at the neuromuscular junction. Innofiller is typically supplied as a lyophilized powder in 100-unit vials for reconstitution and is administered via intramuscular, intradermal, or subdermal injection. It belongs to the broader class of Korean-manufactured botulinum toxins used in cosmetic medicine.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Innofiller.